Our lead program and current focus is on the development of the combination of bemnifosbuvir, a nucleotide analog polymerase ...
Our lead program and current focus is on the development of the fixed dose combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback